A cell-permeable 2,6,9-trisubstituted purine analog that acts as a potent, reversible, and ATP-competitive inhibitor of Cdk1/B with an IC
50 of 20 nM and displays increased potency over purvalanol A (Cat. No.
540500; IC
50 = 50 nM), Roscovitine (Cat. No.
557360; IC
50 = 450 nM), Bohemine (Cat. No.
203600; IC
50 = 1.1 μM) and Olomoucine (Cat. No.
495620; IC
50 = 7.0 μM). Further, exerts greater
in vitro cytotoxicity in various cancer cell lines (IC
50 = 3.0 μM, 5.3 μM, 6.3 μM, 6.3 μM and 11.1 μM for CEM, MCF7, HOS, G631 and K562, respectively).
